Drug intelligence / Profile preview

tranexamic acid + etamsylate

Development stage
Unknown
Lead developer
Biocon
Modality
Small Molecules
Administration
Oral
01

Overview

Albufree TX is a fixed-dose combination pharmaceutical product containing tranexamic acid and etamsylate, primarily utilized in the management of abnormal uterine bleeding and other conditions characterized by excessive blood loss. Tranexamic acid is a synthetic lysine derivative that acts as an antifibrinolytic by competitively inhibiting the activation of plasminogen to plasmin, thereby stabilizing fibrin clots and preventing their premature degradation. Etamsylate (also known as ethamsylate) is a hemostatic agent that enhances platelet adhesion and restores capillary resistance, providing a synergistic effect alongside tranexamic acid to reduce both the duration and volume of hemorrhage. The brand was originally part of Biocon's branded formulations portfolio in India before the division's acquisition by Eris Lifesciences.

Brand names
Albufree TX
Other names
Albufree-TXtranexamic acid + ethamsylate
02

Targets

PLG (Plasminogen)

Beyond the preview

Go deeper on tranexamic acid + etamsylate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tranexamic acid + etamsylate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call